We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+52.54%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$209M
AUM Growth
+$63.1M
Cap. Flow
+$8.28M
Cap. Flow %
3.96%
Top 10 Hldgs %
100%
Holding
15
New
–
Increased
5
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$15.4M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$6.15M
3
EPZM
Epizyme, Inc
EPZM
+$3.21M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$397K
5
UAM
Universal American Corp
UAM
+$43.7K

Top Sells

Rank Stock Value
1
ADAP
Adaptimmune Therapeutics
ADAP
+$8.6M
2
ARDX icon
Ardelyx
ARDX
+$3.75M
3
XLRN
Acceleron Pharma
XLRN
+$1.66M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$1.35M
5
RGNX icon
Regenxbio
RGNX
+$1.25M

Sector Composition

Rank Sector Weight
1 Healthcare 41.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$63.1M 30.14%
1,672,714
+697,429
+72% +$15.4M
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$59.5M 28.42%
3,967,900
– –
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$26.3M 12.56%
802,724
+201,795
+34% +$6.15M
UAM
4
DELISTED
Universal American Corp
UAM
$21.6M 10.3%
2,820,791
+5,908
+0.2% +$43.7K
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$15.2M 7.25%
1,543,118
+351,123
+29% +$3.21M
NSTG
6
DELISTED
NanoString Technologies, Inc.
NSTG
$15M 7.18%
752,857
+25,000
+3% +$397K
NVET
7
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$3.74M 1.78%
900,155
– –
LRMR icon
8
Larimar Therapeutics
LRMR
$384M
$2.52M 1.2%
63,337
– –
OREX
9
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.8M 0.86%
542,755
-1
-0% -$4
BDSI
10
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$608K 0.29%
225,281
-109,958
-33% -$279K
ADAP
11
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-1,054,864
Closed -$8.6M
ARDX icon
12
Ardelyx
ARDX
$1.28B
– –
-428,989
Closed -$3.75M
RGNX icon
13
Regenxbio
RGNX
$511M
– –
-156,741
Closed -$1.25M
XLRN
14
DELISTED
Acceleron Pharma
XLRN
– –
-48,839
Closed -$1.66M
NDRM
15
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-83,211
Closed -$1.35M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q3 2016 Portfolio in Review

As of Q3 2016, Foresite Capital Management II held 15 positions worth $209M, up 43% from $146M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II deployed $8.28M of net new capital in Q3 2016, adding to 5 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 59% a quarter earlier.

On the sell side, the largest reduction was BioDelivery Sciences International, Inc., an estimated $279K trimmed.

  • Foresite Capital Management II added most to Aerie Pharmaceuticals in Q3 2016, an estimated $15.4M increase.
  • Foresite Capital Management II's biggest Q3 2016 reduction was BioDelivery Sciences International, Inc., cutting an estimated $279K.
  • Foresite Capital Management II fully exited Adaptimmune Therapeutics in Q3 2016, selling an estimated $8.6M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $209M portfolio in Q3 2016.
  • Foresite Capital Management II opened 0 new positions and closed 5 in Q3 2016.
  • Foresite Capital Management II's portfolio value rose 43% quarter-over-quarter to $209M.

Based on Foresite Capital Management II's 13F filing for Q3 2016, filed 14 Nov 2016.